TechAnalyzer ProTeva Pharma Industries Ltd ADR TEVA
Stock research in plain language · As of Oct 23, 2026 · updated once a week, after the trading week closes
Daily candles, 50 and 200-day averages and volume · updated every trading day · click to open the live chart
What the company does
Teva Pharma Industries Ltd ADR is a large-cap company in the Healthcare sector (Drug Manufacturers - Specialty & Generic), with a market value of $47.4B, based in the USA.
It employs about 31,173 people and has been listed since Mar 26, 1990.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas.
Cheap or expensive? relatively cheap
The company is loss-making, so it has no P/E — we compare on price-to-sales instead.
Its price-to-sales (P/S) is 2.7 versus 5.5 for the median of the Healthcare sector in our universe (25 companies) — relatively cheap.
Revenue is shrinking 1% versus the same quarter last year.
The average analyst price target is 47.58, 18% above the current price (their view, not ours).
The stock sits at 92% of its one-year range (0% = the low, 100% = the high).
The risks
- • The company is loss-making.
- • Net debt is 1.7× shareholders' equity — high leverage.
- • Quarterly report in 11 days (2026-11-03) — a day the stock can move a lot.
Strengths
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Most analysts rate it buy (12 vs 0).
What changed this week
Over the past week the stock fell 2.2% (for comparison: S&P 500 -1.0%, sector ETF XLV +2.3%).
This week's news
- Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says finance.yahoo.com · 2026-10-20
What the article says
Alvotech (ALVO) has meaningful stock recovery potential as manufacturing progress boosts confidence PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in source ↗
- Teva Pharmaceuticals, Sanofi Report Positive 44-Week Duvakitug Data in Ulcerative Colitis, Crohn's Disease finance.yahoo.com · 2026-10-20
What the article says
Teva Pharmaceutical Industries' (TEVA) affiliate Teva Pharmaceuticals and Sanofi (SNY) said Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in source ↗
- UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease finance.yahoo.com · 2026-10-20
What the article says
Teva Pharmaceutical Industries Ltd In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44 In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at Week 44 Duvakitug was well tolerated and safety was… source ↗
What changed since last week
• New risk flag: earnings report coming up.
• The average analyst target moved from 45.27 to 47.58.
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group. Educational information only — not investment advice. Not a registered investment adviser or broker-dealer.